Trillium Therapeutics Inc. (NASDAQ:TRIL) Given Consensus Rating of “Buy” by Analysts
Trillium Therapeutics Inc. (NASDAQ:TRIL) has received a consensus rating of “Buy” from the six analysts that are covering the firm. Six analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $22.75.
A number of brokerages have recently weighed in on TRIL. BTIG Research began coverage on Trillium Therapeutics in a research report on Thursday. They set a “buy” rating on the stock. Zacks Investment Research upgraded Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Saturday, September 17th. Leerink Swann reiterated an “outperform” rating and set a $20.00 price target on shares of Trillium Therapeutics in a research report on Monday, August 15th. Ladenburg Thalmann began coverage on Trillium Therapeutics in a research report on Wednesday, August 3rd. They set a “buy” rating and a $18.00 price target on the stock. Finally, Cowen and Company reiterated a “buy” rating on shares of Trillium Therapeutics in a research report on Sunday, June 12th.
Trillium Therapeutics (NASDAQ:TRIL) traded up 2.08% during trading on Friday, hitting $16.69. The stock had a trading volume of 143,341 shares. Trillium Therapeutics has a 1-year low of $6.62 and a 1-year high of $17.70. The stock’s market cap is $130.42 million. The firm’s 50-day moving average price is $14.02 and its 200-day moving average price is $10.98.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/trillium-therapeutics-inc-nasdaqtril-given-consensus-rating-of-buy-by-analysts.html
Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in Trillium Therapeutics by 5.7% in the first quarter. Renaissance Technologies LLC now owns 25,478 shares of the company’s stock valued at $236,000 after buying an additional 1,380 shares in the last quarter. Sabby Management LLC acquired a new stake in Trillium Therapeutics during the first quarter valued at approximately $131,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Trillium Therapeutics during the first quarter worth about $100,000. Point72 Asset Management L.P. raised its position in shares of Trillium Therapeutics by 8.6% in the second quarter. Point72 Asset Management L.P. now owns 369,300 shares of the company’s stock worth $3,316,000 after buying an additional 29,300 shares during the last quarter. Finally, EverPoint Asset Management LLC raised its position in shares of Trillium Therapeutics by 43.5% in the second quarter. EverPoint Asset Management LLC now owns 216,000 shares of the company’s stock worth $1,940,000 after buying an additional 65,471 shares during the last quarter. Hedge funds and other institutional investors own 39.34% of the company’s stock.
Trillium Therapeutics Company Profile
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.